Rotavirus vaccine proven to be effective in clinical trials

September 13, 2014

Since August 2011 Medicines Development has been supporting the RV3 Rotavirus Vaccine team at the Murdoch Childrens Research Institute (MCRI) by helping to coordinate the development of MCRI’s novel vaccine to protect newborns from rotavirus infection.

The new rotavirus vaccine candidate has reached a pivotal milestone after clinical trials results found the vaccine provided a strong immune response in over 90 per cent of babies that received a course of the vaccine. This vaccine candidate has been developed in Melbourne and has the potential to save over half a million lives worldwide each year.

Read MCRI media release.